Setema

Setema Therapeutics is a biotechnology company focused on developing novel immunotherapies that target the immunosuppressive tumor microenvironment (TME). Founded by leading experts in immunology, including Dr. Arlene Sharpe, the company aims to overcome the metabolic and physical barriers that prevent effective anti-tumor immune responses. Setema's research primarily centers on the adenosine signaling pathway, which is a key mechanism used by tumors to evade immune detection. By developing therapies that modulate this pathway, the company seeks to "reprogram" the TME and enhance the efficacy of existing and new cancer treatments. Setema is currently in the pre-clinical stage and is backed by the life sciences venture firm Apple Tree Partners. The company is headquartered in Cambridge, Massachusetts, within a prominent biotech ecosystem.